# Is Johnson & Johnson (JNJ) a Buy? — 2026 Fundamental Analysis

> Buy — Defensive healthcare anchor. Johnson & Johnson scores as a Buy: genuinely cheap against its own history with momentum ahead of its sector, while litigation charges hold the quality reading down.

**NOT FINANCIAL ADVICE.** Not financial advice. This is an automated, educational analysis of publicly available data — not a recommendation to buy or sell any security. Do your own research or consult a licensed financial advisor.

**Bottom line (2026-09-08):** Johnson & Johnson (JNJ) scores as a Buy on the FolioFundamentals FolioScore — a proprietary AI and machine-learning model, backtested across 30+ years of market history, with no analyst opinion in the number. The exact live score and entry price are computed at https://foliofundamentals.com/analyzer?s=JNJ

## What JNJ does
Johnson & Johnson is a diversified healthcare leader spanning innovative pharmaceuticals and medical technology (following the Kenvue consumer-health spin-off), with a broad drug pipeline and device franchise.

## FolioScore read, pillar by pillar

| Pillar | JNJ reads as | Why |
|--------|------|-----|
| Valuation | Cheap against itself | Johnson & Johnson trades below its own multi-year average multiple — the pillar doing most of the work in its score, and rare among large-cap defensives. |
| Growth | Steady | Innovative Medicine growth offsets the drag from patent expiries, keeping growth in line with its own trend rather than ahead of it. |
| Quality | Held back by charges | Litigation provisions and separation costs depress reported margin and returns on capital. The underlying business is stronger than this pillar can show. |
| Financial Health | Set aside | The model could not judge this pillar from the latest filings, so it is dropped and the remaining pillars carry the score. |
| Momentum | Ahead of its sector | The share price is running above its own long-term trend and ahead of healthcare generally. |
| Shareholder Returns | Dividend aristocrat | Six decades of increases, comfortably funded. The yield alone will not carry a total-return case, which is why the pillar reads average. |

See the underlying numbers: https://foliofundamentals.com/analyzer?s=JNJ (overview) · https://foliofundamentals.com/analyzer?s=JNJ&tab=charts (charts) · https://foliofundamentals.com/analyzer?s=JNJ&tab=financials (financials)

## Bull case
- A diversified pharma-plus-medtech model reduces reliance on any single drug or device.
- A Dividend King with 60-plus years of consecutive increases and a fortress balance sheet.
- Defensive, recession-resistant demand for healthcare products and therapies.

## Bear case
- Ongoing talc and other litigation creates a hard-to-quantify liability overhang.
- Patent cliffs on key drugs require the pipeline to continually replace expiring revenue.
- Growth is modest, so total return leans heavily on the dividend and buybacks.

## Entry point
JNJ's Valuation pillar and dividend yield tend to look best when litigation headlines or patent-cliff worries push the stock down. Because the underlying cash flows are so stable, those fear-driven de-ratings have historically been the more rewarding entry points for long-term holders.

## Dividend
A cornerstone income holding — a Dividend King with 60+ years of increases, an attractive yield, and one of the few AAA-adjacent balance sheets backing it.

## See the live score
Full 0–100 FolioScore, entry point, 30-year valuation history and 13F institutional holdings for JNJ: https://foliofundamentals.com/analyzer?s=JNJ

_Informational/educational only — not investment advice. The FolioScore is a quantitative starting point, not a buy/sell recommendation._